Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
J Glob Health. 2024 Aug 16;14:04155. doi: 10.7189/jogh.14.04155.
The incidence and mortality of gynaecological cancers can significantly impact women's quality of life and increase the health care burden for organisations globally. The objective of this study was to evaluate global inequalities in the incidence and mortality of gynaecological cancers in 2022, based on The Global Cancer Observatory (GLOBOCAN) 2022 estimates. The future burden of gynaecological cancers (GCs) in 2050 was also projected.
Data regarding to the total cases and deaths related to gynaecological cancer, as well as cases and deaths pertaining to different subtypes of GCs, gathered from the GLOBOCAN database for the year 2022. Predictions for the number of cases and deaths in the year 2050 were derived from global demographic projections, categorised by world region and Human Development Index (HDI).
In 2022, there were 1 473 427 new cases of GCs and 680 372 deaths. The incidence of gynecological cancer reached 30.3 per 100 000, and the mortality rate hit 13.2 per 100 000. The age-standardised incidence of GCs in Eastern Africa is higher than 50 per 100 000, whereas the age-standardised incidence in Northern Africa is 17.1 per 100 000. The highest mortality rates were found in East Africa (ASMR (age-standardised mortality rates) of 35.3 per 100 000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100 000). These are related to the endemic areas of HIV and HPV. Very High HDI countries had the highest incidence of GCs, with ASIR (age-standardised incidence rates) of 34.8 per 100 000, and low HDI countries had the second highest incidence rate, with an ASIR of 33.0 per 100 000. Eswatini had the highest incidence and mortality (105.4 per 100 000; 71.1 per 100 000) and Yemen the lowest (5.8 per 100 000; 4.4 per 100 000). If the current trends in morbidity and mortality are maintained, number of new cases and deaths from female reproductive tract tumours is projected to increase over the next two decades.
In 2022, gynaecological cancers accounted for 1 473 427 new cases and 680 372 deaths globally, with significant regional disparities in incidence and mortality rates. The highest rates were observed in Eastern Africa and countries with very high and low HDI, with Eswatini recording the most severe statistics. If current trends continue, the number of new cases and deaths from gynaecological cancers is expected to rise over the next two decades, highlighting the urgent need for effective interventions.
妇科癌症的发病率和死亡率会显著影响女性的生活质量，并增加全球医疗机构的负担。本研究旨在根据 2022 年全球癌症观察站（GLOBOCAN）的数据，评估全球妇科癌症发病率和死亡率的不平等状况。同时还预测了 2050 年妇科癌症的未来负担。
从 GLOBOCAN 数据库中获取了 2022 年妇科癌症总病例数和死亡人数，以及不同妇科癌症亚型的病例数和死亡人数。根据全球人口预测数据，对 2050 年的病例数和死亡人数进行了预测，并按照世界区域和人类发展指数（HDI）进行了分类。
2022 年，全球新发妇科癌症病例 1473427 例，死亡 680372 例。妇科癌症发病率为 30.3/10 万，死亡率为 13.2/10 万。东非的妇科癌症年龄标准化发病率高于 50/10 万，而北非的年龄标准化发病率为 17.1/10 万。东非的死亡率最高（年龄标准化死亡率为 35.3/10 万），而澳大利亚和新西兰的死亡率最低（8.1/10 万）。这与 HIV 和 HPV 的流行地区有关。HDI 非常高的国家妇科癌症发病率最高，年龄标准化发病率为 34.8/10 万，HDI 低的国家发病率次之，为 33.0/10 万。斯威士兰的发病率和死亡率最高（105.4/10 万；71.1/10 万），也门的发病率和死亡率最低（5.8/10 万；4.4/10 万）。如果维持目前的发病率和死亡率趋势，预计未来二十年女性生殖道肿瘤的新发病例和死亡人数将会增加。
2022 年，全球新发妇科癌症病例 1473427 例，死亡 680372 例，发病率和死亡率存在显著的地区差异。东非和人类发展指数非常高和非常低的国家的发病率和死亡率最高，斯威士兰的统计数据最为严重。如果目前的趋势持续下去，未来二十年妇科癌症的新发病例和死亡人数预计将上升，这突显了采取有效干预措施的迫切需要。
